• Recognition of outstanding in-vivo outcomes from a lead RNA program in CNS
• Underpinned by proprietary IV-formulated, Brain-targeting Ribonucleic Acid Interference (RNAi) Nanomedicine (BTRiN^TM) platform
• BIORCHESTRA to receive in-kind products and services from Merck Group

Since 2014, Merck's Advance Biotech Grant program has recognized innovative biotechnology companies worldwide with this award, by further supporting efforts to improve patient outcomes for diseases such as cancer, brain tumors, osteoarthritis, and cardiovascular disorders.

BIORCHESTRA's Founder, Chairman, and Chief Executive Officer, Dr. Branden Ryu, commented, "We are deeply honored to receive Merck's prestigious grand prize award for 2023 in recognition of the significant in-vivo outcomes achieved from our proprietary IV-formulated, Brain-targeting Ribonucleic Acid Interference (RNAi) Nanomedicine (BTRiN^TM) platform.  BRTiN^TM combines industry-leading and proprietary, IV-formulated RNA chemistries with biological barrier cross and cell targetted delivery of RNA medicine focused on Alzheimer's, Amyotrophic Lateral Sclerosis, and Parkinson's disease."

Key results from our lead ASO and siRNA programs (BMD-001) in 2023 include:

• Evidence of successful intravenous cell-targeted delivery in non-human primates (NHP) and disease amelioration in an Alzheimer's model; and
• Target gene knockdown efficiency in sub-brain regions following intravenous injection.

These promising data are consistent with earlier NHP and rodent study findings that noted broad biodistribution in the brain, coupled with noteworthy neurodegenerative disease target knockdown across multiple measures, driven by a single IV formulation.